An Open-label, Multicentre Study to Compare the Pharmacokinetics of Efanesoctocog Alfa Versus rFVIII Products, Damactocog Alfa Pegol or Turoctocog Alfa Pegol, After a Single Intravenous Dose of 50 IU/kg in a Fixed Sequence in Previously Treated Adults With Severe Haemophilia A
Latest Information Update: 08 Nov 2024
Price :
$35 *
At a glance
- Drugs Efanesoctocog alfa (Primary) ; Damoctocog alfa pegol; Turoctocog alfa pegol
- Indications Haemophilia A
- Focus Pharmacokinetics
- Sponsors Swedish Orphan Biovitrum
- 05 Nov 2024 Planned initiation date changed from 1 Sep 2024 to 1 Nov 2024.
- 04 Sep 2024 New trial record